Centum Targets 13–15% EBITDA as EMS Mix Drags Margins

Centum Electronics Limited — Q4 FY26 Earnings Conference Call (15 May 2026)

1. Overall Tone of Management

Optimistic. Management repeatedly emphasizes “strong execution,” “continued traction,” “robust order book,” and that the company is “entering the next phase of growth from a significantly stronger operational and strategic position.” They also frame overseas restructuring as “progressing broadly in line with our expectations” and “substantially progressing towards closure.”

2. Key Themes from Management Commentary

• Standalone India ESDM focus strengthened
• Standalone FY26 revenue growth ~25% YoY and profitability “improved meaningfully.”
• Strategic sharpening around the “core India ESDM platform.”
• BTS (Build-to-Spec) momentum
• FY26 standalone BTS revenue growth ~37% YoY.
• Order book visibility improving: standalone order book ~INR 1,645 crores (~23% YoY).
• Milestones: HAL UH M AESA radar (lifecycle opportunity >INR 570 crores) and second radar system order for satellite/space debris tracking.
• EMS (Electronics Manufacturing Services) scaling
• FY26 EMS revenue growth ~21% YoY, driven by ramp-up with a leading semiconductor equipment OEM and new wins in industrial/electrification/grid automation/defense export.
• 80+ new product introductions completed to support faster ramp-ups.
• Manufacturing capability expansion: “additional manufacturing lines, process automation… systems integration.”
• Overseas restructuring to remove drag
• Canada: operations discontinued in Q4 FY26; wind-up in progress.
• France: entered redressement judiciaire; court-supervised asset sale with “final bids expected very shortly,” divestment “substantially concluded by July 2026.”
• Financial clarity: “beginning this quarter” overseas subsidiaries classified under discontinued operations.
• Margin narrative tied to mix
• Management attributes margin shortfall to EMS product mix and expects improvement in FY27.

3. Q&A Analysis

Theme A: Margin miss vs prior guidance / mix drivers

• Core question(s):
• Why FY26 standalone margins were ~12.5% vs guided 14–15%, especially as BTS share increased?
• What margin outlook for FY27?
• Management response:
• Target: 13%–15% EBITDA (combined/overall framing).
• Margin below range due to EMS product mix: “initially anticipated a slightly better product mix… some of this will be executed in the current financial year. And with that, we should see better margin from the EMS business in the current year.”
• FY27: maintain 13%–15% EBITDA target; no hard year-by-year guidance beyond medium-term.
• Assessment (evasive/strong/partial):
• Partially evasive: provides mix explanation but limited quantification of how much mix shift drives the delta.
• Strong: clearly ties margin to EMS mix and reiterates the EBITDA target.

Theme B: Overseas divestment / exceptional losses / future write-down risk

• Core question(s):
• Any further exceptional losses expected until French court approval/divestment by July?
• Whether asset sale will generate realization (and whether liabilities will be released).
• Expected quarterly losses from discontinued operations in Q1 FY27.
• Management response:
• No expectation of write-down hitting consolidated books; liabilities exceed assets (“balance sheet carries much larger liabilities… over INR 100 crores excess over assets”).
• “We don’t expect to receive anything” from European asset sale; liabilities held for disposal remain.
• Q1 FY27: loss range uncertain; management suggests not more than Q4 reported and “should not be even at that range,” with deconsolidation potentially by end of Q1 (worst case Q2).
• Assessment:
• Strong/credible on accounting stance: explicitly states discontinued operations classification and lack of expected realization.
• Some uncertainty remains on timing/amount of P&L impact due to court process and consolidation trigger.

Theme C: Growth targets, order inflows, and BTS/EMS execution cycle

• Core question(s):
• FY27 standalone top-line and margins?
• BTS order inflows and whether growth can accelerate given bandwidth freed from overseas.
• Order booking vs revenue timing (book-to-bill, execution cycles).
• Management response:
• Medium-term: 25%–30% growth rate (clarified as standalone, not consolidated).
• BTS order booking: FY26 BTS booked >INR 400 crores; standalone BTS order book visibility ~INR 800-odd crores.
• Capex: INR 40–45 crores next year (with some BTS/R&D emphasis).
• Execution cycle explanation used to manage expectations: BTS longer cycle (2–2.5 years), EMS shorter (~6–9 months execution).
• Assessment:
• Strong: consistent explanation of business model timing.
• Mild evasiveness: avoids giving year-specific order inflow numbers for FY27 beyond qualitative confidence.

Theme D: EMS supply chain constraints (CCL / components)

• Core question(s):
• Are copper clad laminate (CCL) and other component constraints causing bottlenecks?
• Severity trend and procurement geography.
• Management response:
• Supply chain bottlenecks “clearly an emerging theme.”
• CCL lead times increased over last couple of months; mitigation via ordering earlier; supplies still coming “as per our requirement.”
• Procurement diversified across geographies (China/Europe/India depending on segment).
• Assessment:
• Partial: acknowledges lead-time pressure but does not quantify severity beyond “increase” and “monitor closely.”

Theme E: Semiconductor equipment segment scaling and contract specifics

• Core question(s):
• Can they reach USD 30m annual revenue in 2–3 years?
• Details on new semiconductor-related projects (Virupaksha subsystems, space debris radar order size and timeline).
• Management response:
• USD 30m: “progressing quite well… broadly in line,” currently driven by an anchor customer; discussions with other customers “preliminary.”
• Virupaksha: development order <INR 10 crores (antenna array + exciter-receiver subsystems).
• Space debris tracking radar: INR 30-odd crores, long-range radar; execution timeline to FY30/FY31 after development.
• Assessment:
• Strong: provides directional contract breakdown and execution horizon.

Theme F: Defense segment revenue recognition split (BTS vs EMS)

• Core question(s):
• Are defense orders/revenue booked under BTS only, or split with EMS?
• Management response:
• Defense/aerospace appears in both models.
• Standalone: “almost all” BTS numbers are defense/space; but defense contribution also exists in EMS numbers.
• Assessment:
• Clear accounting clarification.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Standalone growth (medium-term): 25%–30% growth rate (reiterated multiple times; clarified as standalone, not consolidated).
• EBITDA margin target: 13%–15% (management “maintain that target”).
• Capex (FY27): INR 40–45 crores (with “50% or could be slightly higher on the BTS segment in terms of R&D capabilities”).
• Standalone order inflow / visibility (qualitative with numbers):
• FY26 BTS booked >INR 400 crores.
• BTS order book visibility: “INR 800-odd crores” in segment.
• BTS execution cycle: 2–2.5 years (used to frame timing of revenue vs order booking).

Implicit signals (qualitative)

• Margin improvement expected in FY27 due to EMS mix: “should see better margin from the EMS business in the current year.”
• Overseas drag likely to fade as discontinued operations classification begins and divestment nears closure.
• EMS supply chain risk: lead-time pressures are being monitored; proactive mitigation in place.
• Growth confidence anchored in order book + pipeline rather than near-term overseas recovery.

5. Standout Statements (direct / highly revealing)

• Overseas realization expectation (strong):
• “We don’t expect to receive anything as a result of this asset sale process.”
• Liabilities vs assets framing (strong):
• “balance sheet carries much larger liabilities… over INR 100 crores excess over assets.”
• Margin miss explanation (specific):
• “slightly below… because of the product mix in the E MS business.”
• Medium-term growth target clarified (important correction):
• “25%, 30% was never at the consolidated level… at the standalone level.”
• BTS order visibility (numerical):
• “close to, I would say, INR 800-odd crores of orders in this segment.”
• EMS supply chain risk acknowledged:
• “supply chain bottlenecks are clearly an emerging theme… need to keep an eye on as this evolves.”
• BTS execution model used to manage expectations:
• “BTS… longer cycle game… from the RFP stage to closure to realizing the revenue.”

6. Red Flags / Positive Signals

Red flags
– Margin guidance credibility risk: FY26 standalone EBITDA margin came in around 12.42% vs earlier guided 14–15%; management attributes to EMS mix but provides limited quantification.
– Overseas P&L timing uncertainty: Q1 FY27 discontinued-operation losses could vary due to court timing; they avoid precise forecasting.
– Supply chain risk not quantified: CCL/component lead times increased, but severity and impact on delivery schedules are not numerically disclosed.

Positive signals
– Clear accounting separation: discontinued operations classification “providing clearer visibility” into continuing core business.
– Order book growth + visibility: standalone order book ~INR 1,645 crores (+23% YoY).
– Concrete program wins: HAL AESA radar milestone and space debris radar order with stated execution horizon.
– Operational metrics improving: adjusted net working capital days improved to 142 days (from 159), ROCE improved to 21.16%.

7. Historical Comparison & Consistency Analysis

a. Change in Tone Over Time

• Current call (Q4 FY26): more confident and “landmark year,” with restructuring “substantially progressing towards closure.”
• Prior calls:
• Q2 H1 FY26 (Nov 2025): still focused on “evaluating options” for Europe and expecting decisions by Q4; subsidiary losses were a key overhang.
• Q3 & 9M FY26 (Feb 2026): tone was decisive on restructuring steps (Canada discontinued; France restructuring initiated), but still emphasized onetime impacts and uncertainty around further losses.
• Classification: More Optimistic vs earlier calls.
• What changed: management now has (1) discontinued operations already underway, (2) divestment timeline (July 2026) and (3) clearer standalone performance narrative.

b. Tracking Past Commitments vs Outcomes

• Past statement (Q2 H1 FY26, Nov 2025): guidance for standalone EBITDA margin 13%–15% and revenue growth ~30% for FY26.
• Expected: achieve margin range by FY26.
• Actual (Q4 FY26): standalone EBITDA margin reported ~12.42% (below range).
• Flag: ❌ Missed / Below guidance (management attributes to EMS mix).
• Past statement (Q2 H1 FY26): Canada decision expected “in a few months… by end of the quarter.”
• Actual: Canada operations discontinued in Q4 FY26; wind-up in progress; discontinued operations classification started earlier (Q3 for Canada).
• Flag: ✅ Delivered (timing broadly aligned with “short duration” narrative).
• Past statement (Q2 H1 FY26): Europe options with direction by end of Q4.
• Actual: France entered redressement judiciaire in March 2026; court-supervised asset sale process ongoing; divestment expected by July 2026.
• Flag: ✅ Delivered directionally, but timing extended into March/July rather than immediate Q4 resolution.

c. Narrative Shifts

• Shift from “subsidiary turnaround” to “exit/closure”
• Earlier calls emphasized stopping losses and evaluating options; now it’s framed as “substantially progressing towards closure” with discontinued operations already separated.
• Margin narrative moved from “operating leverage” to “EMS product mix”
• In earlier calls, margin improvement was discussed more broadly via mix/efficiency; now the miss is explicitly blamed on EMS mix timing.
• Growth target reframed as standalone-only
• Management explicitly corrects that 25%–30% is standalone, not consolidated—important for interpreting prior growth expectations.

d. Consistency & Credibility Signals

• Medium credibility (improving but with misses):
• Credible on restructuring accounting and discontinued operations mechanics.
• Less credible on margin guidance: FY26 came in below guided range with a mix-based explanation that may or may not fully repeat.
• Growth targets are consistent in direction (standalone strong), but management repeatedly avoids granular year-on-year guidance.

e. Evolution of Key Themes

• Demand / order visibility: improving steadily; order book growth emphasized more strongly in Q4 FY26.
• Margins: improving trend at standalone level, but FY26 below target; management now expects improvement via EMS mix in FY27.
• Overseas risk: moved from “headwinds and evaluation” → “restructuring initiated” → “discontinued operations + divestment timeline.”
• Supply chain: newly emphasized as an “emerging theme” in Q4 FY26 (CCL/component lead times), not a major focus in earlier calls.

f. Additional Insights (cross-period intelligence)

• The “guidance miss” is likely structural timing, not demand collapse: management’s explanation is EMS mix execution timing (“executed in the current financial year”), suggesting demand exists but product ramp timing affects margin.
• Overseas drag is being neutralized via accounting classification, not operational turnaround: the company’s improved consolidated story is increasingly driven by discontinued operations separation rather than fully fixing overseas profitability.
• Risk is shifting from Europe/Canada to EMS supply chain execution: as overseas risk fades, operational execution risks (lead times, component availability) become more prominent.